Last reviewed · How we verify
Placebo (for Empagliflozin)
Placebo produces no pharmacological effect and serves as an inert control in clinical trials.
Placebo produces no pharmacological effect and serves as an inert control in clinical trials. Used for Control arm in clinical trials for Empagliflozin efficacy assessment.
At a glance
| Generic name | Placebo (for Empagliflozin) |
|---|---|
| Also known as | Placebo, Sugar pill |
| Sponsor | University of Texas Southwestern Medical Center |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inactive substance used as a comparator in randomized controlled trials to assess the efficacy of an active drug (in this case, Empagliflozin) by isolating the true drug effect from placebo response and natural disease progression. It allows researchers to determine whether observed clinical benefits are attributable to the active drug's mechanism rather than patient expectation or other non-specific factors.
Approved indications
- Control arm in clinical trials for Empagliflozin efficacy assessment
Common side effects
Key clinical trials
- A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension (PHASE1)
- Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) (NA)
- SGLT2i, Pioglitazone, and Ketone Production in T2D (PHASE1)
- Empagliflozin in Hypertrophic Cardiomyopathy (PHASE3)
- CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients (PHASE2)
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (PHASE2)
- Empagliflozin in Patients With Cirrhosis and Ascites (PHASE2)
- Empagliflozin Reversal of Arterial StiffnEss in Aging (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: